Adjusted mean change (SE) in patient-reported outcomes from baseline to week 52 by disease status
| PRO measure | Did not achieve LDA* (n = 249) | Achieved LDA but not remission* (n = 74) | Achieved remission*‡ (n = 205) | Overall p value† |
| HAQ | −0.59 (0.04) | −0.98 (0.07) | −1.28 (0.04) | <0.0001 |
| EQ-5D utility | 0.20 (0.02) | 0.36 (0.03) | 0.44 (0.02) | <0.0001 |
| EQ-5D VAS | 10.84 (1.47) | 24.62 (2.65) | 36.04 (1.44) | <0.0001 |
| Fatigue VAS | −12.81 (1.59) | −25.62 (2.72) | −40.71 (1.62) | <0.0001 |
| Pain VAS | 21.04 (1.50) | 43.94 (2.51) | 52.51 (1.50) | <0.0001 |
| HADS depression | −1.08 (0.24) | −2.36 (0.41) | −3.67 (0.24) | <0.0001 |
| HADS anxiety | −1.54 (0.25) | −1.50 (0.42) | −3.25 (0.24) | <0.0001 |
| SF-36 PCS | 6.78 (0.63) | 13.69 (1.04) | 18.61 (0.61) | <0.0001 |
| SF-36 MCS | 3.38 (0.72) | 6.76 (1.19) | 10.03 (0.70) | <0.0001 |
EQ-5D, EuroQol health assessment; HADS, Hospital Anxiety and Depression Scale; HAQ, Health Assessment Questionnaire; LDA, low disease activity; MCS, mental component summary; PCS, physical component summary; PRO, patient-reported outcome; SE, standard error; SF-36, Medical Outcomes Short-Form 36; VAS, visual analogue scale.
*Pairwise comparisons between groups were all statistically significant at p⩽0.012 except for HADS anxiety for “did not achieve LDA” versus the “LDA but no remission” groups (not significant).
†Analysed by ANCOVA, including terms for age, sex and baseline score.
‡Remission as defined by disease activity score using 28 joint counts (DAS28) criteria.